Key Players
Competitive Landscape
Four developer types compete in Treg therapy: engineered autologous cell companies, allogeneic cell specialists, expanded polyclonal programs and in vivo Treg-biologic developers.
Investment has moved toward late-stage autoimmune trials and automated manufacturing since 2025 as sponsors prepare larger programs. In July 2026, Nektar Therapeutics launched two 510-patient Phase 3 ZENITH AD trials and Sonoma Biotherapeutics entered a Cellares collaboration to automate SBT-77-7101 production. Developers now compete on clinical maturity and target specificity as scalable analytical control determines readiness for larger programs.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Nektar Therapeutics initiated two 510-patient ZENITH AD Phase 3 trials in July 2026 | Large autoimmune programs need repeatable dosing without patient collection | In vivo Treg stimulation enters registrational testing | Chronic autoimmune indications using repeat injectable dosing |
| Sonoma Biotherapeutics and Cellares agreed in July 2026 to automate SBT-77-7101 manufacturing | Autologous Tregs require consistent expansion and release testing | Automated closed manufacturing reaches Treg programs | Manufacturing transfer and quality-control services |
| Quell Therapeutics initiated the multinational CHILL Phase 1/2 study in March 2026 | Complex autoimmunity needs localized suppression across several immune pathways | CAR-Tregs expand beyond organ transplantation | Disease-specific programs across European clinical networks |
Abata Therapeutics, Cellenkos Inc., Coya Therapeutics, Sangamo Therapeutics and Singulera Therapeutics remain active in antigen-specific cells, donor-derived products, biologics and expanded autologous Tregs, with no dated developments recorded during this period.
Source: Future Market Insights, Treg Therapy Market and Cell Therapy Manufacturing Market reports, 2026-2036.
Eight companies cover in vivo stimulation, engineered antigen-directed cells, donor-derived products and expanded autologous Tregs across autoimmune and transplant programs.
Which programs are furthest into clinical development?
Nektar Therapeutics has entered global Phase 3 development through two 510-patient rezpegaldesleukin trials in atopic dermatitis. Coya Therapeutics has reached Phase 2 with COYA 302, while engineered cell programs remain in Phase 1 or Phase 1/2.
Which companies use antigen-directed engineered Tregs?
Abata Therapeutics uses a TCR-engineered autologous product for progressive multiple sclerosis in a Phase 1 study. Quell Therapeutics, Sonoma Biotherapeutics and Sangamo Therapeutics use CAR-Treg designs directed toward transplant or disease-associated antigens in clinical programs.
Which companies avoid patient-specific cell collection?
Cellenkos Inc. develops an allogeneic cord-blood Treg product that avoids collecting cells from every treated patient. Nektar Therapeutics and Coya Therapeutics use injectable biologics that increase Treg number or function inside treated patients.
Which companies support multinational trials or scalable manufacturing?
Quell Therapeutics runs QEL-005 across the United Kingdom, Germany and Spain in a multinational Phase 1/2 study. Nektar Therapeutics operates a global Phase 3 program, while Sonoma Biotherapeutics uses Cellares for automated manufacturing with capacity planned in Europe and Japan.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Nektar Therapeutics | Global clinical development | Rezpegaldesleukin selectively stimulates Tregs in vivo. Phase 3 began in 2026. |
| Quell Therapeutics | United Kingdom and Europe | QEL-001 and QEL-005 are autologous CAR-Treg products in Phase 1/2 studies. |
| Sonoma Biotherapeutics | United States | SBT-77-7101 targets citrullinated proteins. Phase 1 manufacturing transfer began in 2026. |
| Abata Therapeutics | United States | ABA-101 is a TCR-engineered autologous Treg product in Phase 1 for progressive multiple sclerosis. |
| Sangamo Therapeutics | Europe | TX200 is an HLA-A2 CAR-Treg product with Phase 1/2 kidney-transplant development. |
| Cellenkos Inc. | United States | CK0801 is an allogeneic cord-blood Treg product registered for Phase 2 aplastic-anemia development. |
| Coya Therapeutics | United States and Canada | COYA 302 combines low-dose IL-2 and CTLA-4 Ig in an active Phase 2 ALS study. |
| Singulera Therapeutics | United States and Taiwan | TRK-001 uses expanded autologous Tregs in a multinational Phase 2 kidney-transplant study. |
Research Methodology
The companies here show how Treg therapy competition is structured without ranking active development programs. Inclusion requires evidence that each company develops a Treg cell product or biologic for immune-tolerance use. Evidence comes from official company websites, clinical trial records, filings, press releases and regulatory records. Trial phases apply to named products and indications, while geographic reach records active study regions. Shares are FMI estimates, with polyclonal Treg therapy accounting for 43.0% of therapy type demand in 2026.
